0.02
+0.009(+81.82%)
Currency In USD
| Previous Close | 0.01 |
| Open | 0.02 |
| Day High | 0.02 |
| Day Low | 0.02 |
| 52-Week High | 0.97 |
| 52-Week Low | 0 |
| Volume | 10,000 |
| Average Volume | 9,342 |
| Market Cap | 2.49M |
| PE | -0.01 |
| EPS | -1.54 |
| Moving Average 50 Days | 0.11 |
| Moving Average 200 Days | 0.26 |
| Change | 0.01 |
If you invested $1000 in NKGen Biotech, Inc. Common Stock (NKGN) since IPO date, it would be worth $3.5 as of October 18, 2025 at a share price of $0.02. Whereas If you bought $1000 worth of NKGen Biotech, Inc. Common Stock (NKGN) shares 1 year ago, it would be worth $50.03 as of October 18, 2025 at a share price of $0.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
GlobeNewswire Inc.
Oct 09, 2025 12:05 PM GMT
SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
GlobeNewswire Inc.
Oct 06, 2025 12:05 PM GMT
SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum
GlobeNewswire Inc.
Sep 18, 2025 12:05 PM GMT
SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natura